nach oben

Drugs in R&D

Erschienen in:

01.11.2008 | Review Article

Histone Deacetylation

An Attractive Target for Cancer Therapy?

verfasst von: Anas Al-Janadi, Sreenivasa R. Chandana, Dr Barbara A. Conley

Erschienen in: Drugs in R&D | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Recent research has elucidated another mechanism for gene expression and signalling protein regulation in malignant cells. Histone deacetylases (HDACs) have been associated with silencing of tumour suppressor genes, and with other functions that promote malignant cell phenotype, such as the function of the chaperone protein heat shock protein (HSP)-90. Malignant cells overexpress some HDACs, and aberrant gene products have been shown to recruit HDACs to DNA to accomplish silencing of differentiation in other genes. Several chemical classes of small molecule inhibitors of HDAC have been synthesized, including small chain fatty acids, benzamides, hydroxamic acids and hybrid molecules. All have shown preclinical activity in vitro and/or in vivo in nanomolar to micromolar concentrations. Some have shown activity in clinical trials. One (vorinostat; suberoylanalide hydroxamic acid [SAHA]) has been approved by the US FDA for therapy of T-cell lymphomas. HDAC inhibitors show the most promising activity as single agents in haematological malignancies rather than solid tumours. Clinical trials testing combinations of HDAC inhibitors with other antineoplastic agents and with demethylating agents have shown promising results. HDAC inhibitors also seem to enhance radiation effects on malignant tissue, while potentially sparing toxicity to normal tissues. In this article, we review the rationale for development of HDAC inhibitors as therapy for malignant diseases, as well as the preclinical and clinical trial data for some HDAC inhibitors under development.

Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000 Jul; 184 (1): 1–16PubMedCrossRef

Schultz BE, Misialek S, Wu J, et al. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 2004 Aug 31; 43 (34): 11083–91PubMedCrossRef

Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495–528PubMedCrossRef

Kim TY, Bang YJ, Robertson KD. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006 Jan–Mar; 1 (1): 14–23PubMedCrossRef

Yang WM, Yao YL, Sun JM, et al. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997 Oct 31; 272 (44): 28001–7PubMedCrossRef

Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000 Aug 2; 92 (15): 1210–6PubMedCrossRef

Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005 Jun 10; 23 (17): 3971–93PubMedCrossRef

Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006 Aug 15; 107 (4): 832–40PubMedCrossRef

McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 2004 Sep 15; 68 (6): 1139–44PubMedCrossRef

10.

Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005 Mar 8; 102 (10): 3697–702PubMedCrossRef

11.

Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007 Oct; 4 (5): 337–43PubMed

12.

Gabrielli B, Warrener R, Burgess A, et al. Defining the chemotherapeutic targets of histone deacetylase inhibitors. Ann N Y Acad Sci 2004 Dec; 1030: 627–35PubMedCrossRef

13.

Qiu L, Burgess A, Fairlie DP, et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000 Jun; 11 (6): 2069–83PubMed

14.

Khan AN, Tomasi TB. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res 2008; 40 (2): 164–78PubMedCrossRef

15.

Karagiannis TC, El-Osta A. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 2006 Jul–Sep; 1 (3): 121–6PubMedCrossRef

16.

Bhalla K, List A. Histone deacetylase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 2004 Dec; 17 (4): 595–611PubMed

17.

Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 Sep; 5 (9): 769–84PubMedCrossRef

18.

Lin RJ, Sternsdorf T, Tini M, et al. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001 Oct 29; 20 (49): 7204–15PubMedCrossRef

19.

Jabbour EJ, Giles FJ. New agents in myelodysplastic syndromes. Curr Hematol Rep 2005 May; 4 (3): 191–9PubMed

20.

Shaker S, Bernstein M, Momparler LF, et al. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 2003 May; 27 (5): 437–44PubMedCrossRef

21.

Nimmanapalli R, Fuino L, Stobaugh C, et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003 Apr 15; 101 (8): 3236–9PubMedCrossRef

22.

Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001 Dec 17; 20 (24): 6969–78PubMedCrossRef

23.

Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004 Sep 1; 104 (5): 1266–9PubMedCrossRef

24.

Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008 Apr; 7 (4): 759–68PubMedCrossRef

25.

Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leuke-mias and myelodysplastic syndromes. Blood 2008 Feb 1; 111 (3): 1060–6PubMedCrossRef

26.

Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005 Feb 1; 105 (3): 959–67PubMedCrossRef

27.

Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008 Feb 1; 14 (3): 826–32PubMedCrossRef

28.

Thatikonda C, Rossetti JM, Shadduck RK, et al. Combination methyltransferase and histone deacetylase inhibition in elderly patients with secondary acute myelogenous leukemia [abstract]. Blood 2007; 110: 4387

29.

HDAC inhibitors: NIH [online]. Available from URL: http://clinicaltrials.gov [Accessed 2008 Sep 22]

30.

Garcia-Manero G, Yang AS, Klimek VM, et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute mye-logenous leukemia (AML) [abstract]. Blood 2007; 110: 444

31.

Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008 Jan 15; 409 (2): 581–9PubMedCrossRef

32.

Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999 Aug 15; 94 (4): 1401–8PubMed

33.

Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003 Jul 15; 102 (2): 652–8PubMedCrossRef

34.

Lucas DM, Davis ME, Parthun MR, et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004 Jul; 18 (7): 1207–14PubMedCrossRef

35.

Sakajiri S, Kumagai T, Kawamata N, et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005 Jan; 33 (1): 53–61PubMedCrossRef

36.

Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007 May 8; 104 (19): 8071–6PubMedCrossRef

37.

Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005 Jun 10; 23 (17): 3923–31PubMedCrossRef

38.

O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006 Jan 1; 24 (1): 166–73PubMedCrossRef

39.

Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008 May; 19 (5): 964–9PubMedCrossRef

40.

Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005 Nov; 125 (5): 1045–52PubMedCrossRef

41.

Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007 Jan 1; 109 (1): 31–9PubMedCrossRef

42.

Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007 Jul 20; 25 (21): 3109–15PubMedCrossRef

43.

Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lympthoma. Clin Cancer Res 2008 14 (14) Jul 15: 4500–10PubMedCrossRef

44.

Whittaker S, McCulloch W, Robak T, et al. International multicenter phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): interim report [abstract no. 3063]. Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology;2006 Jun 2–6; Atlanta (GA). J Clin Oncol 2006, 24 (18S): 136s

45.

Kelly WK, Richon VM, O’Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003 Sep 1; 9 (10 Pt 1): 3578–88PubMed

46.

Thompson LM, Plummer S, Schalling M, et al. A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics 1991 Dec; 11 (4): 1133–42PubMedCrossRef

47.

Stec I, Wright TJ, van Ommen GJ, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998 Jul; 7 (7): 1071–82PubMedCrossRef

48.

Marango J, Shimoyama M, Nishio H, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008 Mar 15; 111 (6): 3145–54PubMedCrossRef

49.

Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006 Nov 15; 108 (10): 3441–9PubMedCrossRef

50.

Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004 Jan 13; 101 (2): 540–5PubMedCrossRef

51.

Lavelle D, Chen YH, Hankewych M, et al. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001 Nov; 68 (3): 170–8PubMedCrossRef

52.

Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008 Mar; 49 (3): 502–7PubMedCrossRef

53.

Galli M. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma [abstract]. Blood 2007 110: 1175CrossRef

54.

Pei XY, Dai Y, 1S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004 Jun 1; 10 (11): 3839–52PubMedCrossRef

55.

Badros A, Philip S, Niesvizky R, et al. Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib in relapsed multiple myeloma patients [abstract]. Blood 2007; 110: 1168CrossRef

56.

Weber DM, Jagannath S, Mazumder A, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma [abstract]. Blood 2007; 110: 1172

57.

Prince M, Quach H, Neeson P, et al. Safety and efficacy of the combination of bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma [abstract]. Blood 2007; 110: 1167

58.

Guerini V, Barbui V, Spinelli O, et al. Selective targering of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor [abstract]. Blood 2007; 110: 555

59.

Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008 Mar 15; 14 (6): 1669–77PubMedCrossRef

60.

Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006 May 12; 281 (19): 13548–58PubMedCrossRef

61.

Tumber A, Collins LS, Peterson KD, et al. The histone deactylase inhibitor PXD101 synergizes with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 2007 Jul; 60 (2) 275–83PubMedCrossRef

62.

Sung MW, Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007 Mar–Apr; 27 (2): 995–1001PubMed

63.

Pulukuri SM, Gorantla B, Rao JS. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 2007 Dec 7; 282 (49): 35594–603PubMedCrossRef

64.

Richards DA, Boehm KA, Waterhouse DM, et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006 Jul; 17 (7): 1096–102PubMedCrossRef

65.

Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008 Feb; 9 (2): 139–48PubMedCrossRef

66.

Venturelli S, Armeanu S, Pathil A, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007 May 15; 109 (10): 2132–41PubMedCrossRef

67.

Baradari V, Huether A, Hopfner M, et al. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006 Dec; 13 (4): 1237–50PubMedCrossRef

68.

Digel W, Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 2005 Jul; 55 (1): 1–11PubMedCrossRef

69.

Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin Cancer Res 2008 Jan 1; 14 (1): 188–98PubMedCrossRef

70.

Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005 Mar; 90 (1): 15–23PubMedCrossRef

71.

Fan J, Yin WJ, Lu JS, et al. ERalpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 2008 Aug; 134 (8): 883–90PubMedCrossRef

72.

Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 2007 Jan; 6 (1): 64–9PubMedCrossRef

73.

Sharma D, Saxena NK, Davidson NE, et al. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 2006 Jun 15; 66 (12): 6370–8PubMedCrossRef

74.

Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 2004 Mar 4; 23 (9): 1724–36PubMedCrossRef

75.

Joung KE, Min KN, An JY, et al. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice. Cancer Res 2006 May 15; 66 (10): 5394–402PubMedCrossRef

76.

Vigushin DM, Ali S, Pace PE, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001 Apr; 7 (4): 971–6PubMed

77.

Munster PN, Troso-Sandoval T, Rosen N, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001 Dec 1; 61 (23): 8492–7PubMed

78.

Hodges-Gallagher L, Valentine CD, Bader SE, et al. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007 Nov; 105 (3): 297–309PubMedCrossRef

79.

Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007 Aug 15; 13 (16): 4882–90PubMedCrossRef

80.

Chinnaiyan P, Varambally S, Tomlins SA, et al. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int J Cancer 2006 Feb 15; 118 (4): 1041–50PubMedCrossRef

81.

Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008 Feb 12; 98 (3): 604–10PubMedCrossRef

82.

Modesitt SC, Sill M, Hoffman JS, et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 109 (2): 182–6PubMedCrossRef

83.

Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer: a phase I study [abstract]. Mol Cancer 2005 Jul 7; 4 (1): 22PubMedCrossRef

84.

Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007 Jul 16; 97 (2): 177–82PubMedCrossRef

85.

Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007 May 20; 25 (15): 1979–85PubMedCrossRef

86.

Pauer LR, Olivares J, Cunningham C, et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004; 22 (6): 886–96PubMedCrossRef

87.

Undevia SD, Kindler HL, Janisch L, et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol 2004 Nov; 15 (11): 1705–11PubMedCrossRef

88.

Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006 Jan; 7 (4): 257–61PubMedCrossRef

89.

Vansteenkiste J, van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008; 26 (5): 483–8PubMedCrossRef

90.

Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007 Jun 15; 13 (12): 3605–10PubMedCrossRef

91.

Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005 Jun 10; 23 (17): 3912–22PubMedCrossRef

92.

Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007 Sep 15; 13 (18 Pt 1): 5411–7PubMedCrossRef

93.

Fouladi M, Furman WL, Chin T, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J Clin Oncol 2006 Aug 1; 24 (22): 3678–85PubMedCrossRef

94.

Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006 Jul 1; 12 (13): 3997–4003PubMedCrossRef

95.

Stadler WM, Margolin K, Ferber S, et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006 Jun; 5 (1): 57–60PubMedCrossRef

96.

Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008 Feb 1; 14 (3): 804–10PubMedCrossRef

97.

Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008 Apr 20; 26 (12): 1940–7PubMedCrossRef

Titel: Histone Deacetylation
An Attractive Target for Cancer Therapy?
verfasst von: Anas Al-Janadi
Sreenivasa R. Chandana
Dr Barbara A. Conley
Publikationsdatum: 01.11.2008
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 6/2008
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/0126839-200809060-00003

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Histone Deacetylation

An Attractive Target for Cancer Therapy?

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate

Irsogladine is Effective for Recurrent Oral Ulcers in Patients with Behçet’s Disease

New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development

Acknowledgement

Has Molecular and Cellular Imaging Enhanced Drug Discovery and Drug Development?

New Approaches to the Treatment of Inflammatory Disease